Zydus Lifesciences Limited said on Wednesday, March 18, that it has entered into a Licensing and Supply Agreement with Torrent Pharmaceuticals Limited to co-market Semaglutide Injection in the Indian market.
Under the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market it in India under its own brand name Sembolic, as per the exchange filing. Zydus will market the product under its brands Semaglyn, Mashema, and Alterme.
As part of the arrangement, Torrent Pharma will pay an upfront licensing fee to Zydus.
The pharma company (Zydus) said that it has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable patient-friendly pen device, enabling delivery of all strengths for both indications through a single device platform.
It added that the formulation combined with the reusable pen device
is designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance, addressing key challenges in chronic disease management.
Semaglutide is indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, either as monotherapy where metformin is inappropriate or in in addition to other medicinal products for the treatment of diabetes, informed the firm.
It is also indicated for use in adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) in the presence of at least one weight-related comorbidity.
Also Read: Zydus unit licenses experimental drug to treat rare rapid-ageing disease in children
The firm added that the partnership combines its (Zydus) product development and manufacturing capabilities with Torrent Pharma’s market reach, with the aim of improving patient access to GLP-1 therapies for metabolic disorders in India.
Earlier, on March 17, Zydus had announced the licensing and supply agreement with Lupin to co-market an innovative semaglutide injection in India. The partnership will cover semaglutide injection (15 mg/3 ml) delivered through a patient-friendly reusable pen device, the firm had said.
